The Liposome Company
Executive Summary
Registers for 3 mil. share secondary offering. Proceeds will fund clinical testing of Mycobacterium avium-intracellulare treatment TLC G-62 and the sepsis/acute myocardial infarction/adult respiratory distress syndrome treatment TLC C-53.